EDIT vs BEAM
EDIT and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $258.47M | $2.67B |
| P/B | — | 2.29 |
| P/S | 6.4x | 19.1x |
| Revenue | — | $164.01M(TTM) |
| Revenue growth (YoY) | 25.4% | 120.0% |
| Net income | — | -$65.98M(TTM) |
| Earnings growth (YoY) | 32.5% | 78.8% |
| EPS, diluted | — | $-0.49(TTM) |
| EBIT margin | -394.9% | -274.6% |
| ROE | -3631.1% | -6.9% |
| ROIC | — | -39.3% |
| 1y total return | +8.0% | +37.7% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: EDIT frente a BEAM
| Métrica | EDIT | BEAM |
|---|---|---|
| Valor final | $945 | $13.8K |
| Retorno total | -90.5% | +38.2% |
| CAGR | -30.5% | +5.1% |
| Volatilidad | 92.6% | 80.1% |
| Sharpe | 0.00 | 0.41 |
| Sortino | 0.01 | 0.63 |
| Caída máxima | -98.9% | -89.1% |
Basado en 1630 días de negociación comunes, 2020-02-06 → 2026-08-03 · tasa libre de riesgo 3.91% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)